These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23656803)

  • 21. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.
    Burmester JK; Berg RL; Glurich I; Yale SH; Schmelzer JR; Caldwell MD
    Clin Med Res; 2011 Nov; 9(3-4):119-24. PubMed ID: 21562135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.
    Saito R; Takeda K; Yamamoto K; Nakagawa A; Aoki H; Fujibayashi K; Wakasa M; Motoyama A; Iwadare M; Ishida R; Fujioka N; Tsuchiya T; Akao H; Kawai Y; Kitayama M; Kajinami K
    J Thromb Thrombolysis; 2014 Jul; 38(1):105-14. PubMed ID: 23928870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA
    Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction.
    Carlquist JF; Horne BD; Mower C; Park J; Huntinghouse J; McKinney JT; Muhlestein JB; Anderson JL
    J Thromb Thrombolysis; 2010 Oct; 30(3):358-64. PubMed ID: 20499136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves.
    Lee KE; Chung JE; Yi B; Cho YJ; Kim HJ; Lee GY; Kim JH; Chang BC; Gwak HS
    Int J Cardiol; 2017 Jun; 236():393-397. PubMed ID: 28262345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
    Borgiani P; Ciccacci C; Forte V; Sirianni E; Novelli L; Bramanti P; Novelli G
    Pharmacogenomics; 2009 Feb; 10(2):261-6. PubMed ID: 19207028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population.
    Issac MS; El-Nahid MS; Wissa MY
    Mol Diagn Ther; 2014 Feb; 18(1):73-83. PubMed ID: 24092646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.
    Sagreiya H; Berube C; Wen A; Ramakrishnan R; Mir A; Hamilton A; Altman RB
    Pharmacogenet Genomics; 2010 Jul; 20(7):407-13. PubMed ID: 20442691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses.
    Chung JE; Lee KE; Chang BC; Gwak HS
    Gene; 2018 Jan; 641():68-73. PubMed ID: 29054760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
    Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA
    Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Genetics of Warfarin Dose-Response Variability in Africans: An Expert Perspective on Past, Present, and Future.
    Ndadza A; Thomford NE; Mukanganyama S; Wonkam A; Ntsekhe M; Dandara C
    OMICS; 2019 Mar; 23(3):152-166. PubMed ID: 30883300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.
    Mazzaccara C; Conti V; Liguori R; Simeon V; Toriello M; Severini A; Perricone C; Meccariello A; Meccariello P; Vitale DF; Filippelli A; Sacchetti L
    PLoS One; 2013; 8(8):e71505. PubMed ID: 23990957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
    McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
    Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.